Safety and Efficacy of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ Enriched Cell Fraction That Contains CD34+ Cells Transduced ex Vivo With the GLOBE1 Lentiviral Vector Expressing the βAS3 Globin Gene in Patients With Sickle Cell Disease (DREPAGLOBE)

Sickle Cell Disease Clinical Trial

— DREPAGLOBE  

Official title:

A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ Enriched Cell Fraction That Contains CD34+ Cells Transduced ex Vivo With the GLOBE1 Lentiviral Vector Expressing the βAS3 Globin Gene (GLOBE1 βAS3 Modified Autologous CD34+ Cells) in Patients With Sickle Cell Disease (SCD)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03964792
• Other study ID #: P170006J
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: November 12, 2019
• Est. completion date: January 2024

Study information

• Verified date: January 2024
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the Safety and Efficacy of Gene Therapy of the Sickle Cell disease by Transplantation of an Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced ex vivo with the GLOBE1 lentiviral vector expressing the βAS3 globin gene (GLOBE1 βAS3 Modified Autologous CD34+ Cells) in Patients with Sickle Cell Disease (SCD)

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 6
• Est. completion date: January 2024
• Est. primary completion date: July 28, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 20 Years

Eligibility

Inclusion Criteria:

• - Age 12-20 years

• Diagnosis of HbSS or S-beta zero thalassemia by Hb electrophoresis or genetic analysis.

• Clinical history or ongoing evidence of severe sickle cell anemia with one OR more of the following clinical complications demonstrating disease severity:

• At least 3 vaso occlusive crises requiring hospitalization, under hydroxyurea or transfusion, within 2 years prior to enrollment

• One severe acute chest syndrome (ACS) hospitalized in intensive care unit

• At least 2 episodes of ACS within the prior 3 years), including one under HU.

• Acute priapism (at least 2 episodes > 3h in the preceding year or in the year prior to the start of a regular transfusion program), OR stuttering priapism = 1 by week under sickle cell treatment (HU, transfusion or phlebotomy).

• Cerebral vasculopathy confirmed by MRA (magnetic resonance angiography) without Moya-moya

• Presence of sickle cell cardiomyopathy documented by Doppler echocardiography (left ventricular ejection fraction (LVEF) <55% AND tricuspid regurgitation velocity >2.5m/s on cardiac echocardiograph),

• Tricuspid regurgitation velocity >2.8m/s on cardiac echocardiograph without pulmonary hypertension confirmed by right heart catheterization (mPAP<25mmHg)

• Failed hydroxyurea (HU) therapy, were unable to tolerate HU therapy, or, if 18 years of age or older, have actively made the choice to not take the recommended daily HU regimen. Inadequate clinical response to HU, defined as any one of the following outcomes, while on HU for at least 3 months: 2 or more acute sickle pain crises requiring hospitalization, no rise in Hb >1.5 gm/dl from pre-HU baseline or requires transfusion to maintain Hb > 6.0 gm/dL, had an episode of ACS despite adequate supportive care measures.

• Karnovsky/Lansky performance score = 60%

• Sexually active patients must be willing to use an acceptable method of double-barrier contraception for at least 12 months post-infusion (beyond 12 months at the discretion of the investigator)

Exclusion Criteria:

• Chromosomal (karyotyping) or molecular anomalies (detected by NGS) ( ie 7 chromosomal monosomy)

• Existence of a matched sibling donor

• Patients who have started new treatment for SCD within 6months of enrollment

• Hematologic evaluation: Leukopenia (WBC < 3000 µL) ( en cours) or neutropenia (ANC < 1000 µL) or thrombocytopenia (platelet count < 100,000 µL) (not due to an erythropheresis procedure)

• PT/INR or PTT > 1.5 times upper limit of normal (ULN) or clinically significant bleeding disorder

• Evaluations within 6 months prior to screening visit:

• ALT or AST > 3 times ULN

• Liver Cirrhosis suspicion on echography, CT scan or MRI AND confirmed by histology

• Cardiac evaluation: LVEF < 40% by cardiac echocardiogram or by MUGA scan

• Stroke with significant CNS sequelae i.e., Rankin > 2

• Lung interstitial infiltrate AND Forced Vital Capacity less than 70% AND DLCO less than 60% at steady state

• Confirmed pulmonary hypertension defined by a right heart catheterization (PAPm>25mmHg). Right heart catheterization is required if tricuspid regurgitation velocity >2.8m/s on cardiac echocardiograph OR >2.5m/s with an abnormal Brain Natriuretic Peptide dosage or an important decrease in transcutaneous Hb O2 saturation during the 6 minutes walk test.

• Seropositivity for HIV (Human Immunodeficiency Virus), HCV (Hepatitis C Virus), HTLV-1 (Human T-Lymphotropic Virus), or active Hepatitis B Virus, or active infection by CMV or parvovirus B19, based on positive blood PCR.

• Pregnancy or breastfeeding in a postpartum female

• Any current cancer or prior history of a malignant disease, with the exception of curatively treated non-melanoma skin cancer

• Immediate family member with an established or suspected Familial Cancer Syndrome

• Diagnosis of significant psychiatric disorder of the subject that could seriously impeded the ability to participate in the study

• Patients who failed previous HSCT and are severely ill

• Any clinically significant active infection

• Participation in another clinical study with an investigational drug within 30 days of screening

• Any condition, based on perspective of the medical monitor and treating investigator, which may lead to increased safety risk or inability to comply with the protocol

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Sickle Cell Disease

Intervention

Genetic:
• DREPAGLOBE drug product
Each patient will receive a single IV infusion of DREPAGLOBE drug product

Locations

Country	Name	City	State
France	Department of Biotherapy, Necker-Enfants Malades Hospital	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of transplant related mortality	To evaluate the procedure safety	up to 100 days post treatment
Primary	Incidence of the need for rescue autologous bone marrow transplant	To evaluate the procedure safety	up to 100 days post treatment
Primary	Frequency and severity of AEs post transplant transplant	Based on the United States national Cancer Institute Common Terminology Criteria for Adverse Events v4.03 To evaluate the procedure safety	6 months post-transplant
Primary	Incidence of vector-derived Replication competent lentivirus (RCL)	To evaluate the procedure safety	6 months post-transplant
Primary	Incidence of clinically detectable malignancy and/or abnormal clonal dominance assessed as related to study treatment	To evaluate the procedure safety.It will be evaluated by vector insertion site analysis (VISA.	6 months post-transplant
Secondary	Concentration of neutrophil	To evaluate the efficacy	6 months post-transplant
Secondary	Concentration of platelet	To evaluate the efficacy. It will be quantified by High performance liquid chromatography	6 months post-transplant
Secondary	Percentage HbAS3	To evaluate the efficacy. It will be quantified by High performance liquid chromatography It will be quantified by High performance liquid chromatography	6 months post-transplant
Secondary	Frequency and severity of adverse events	based on the United States national Cancer Institute Common Terminology Criteria for Adverse Events v4.03 To evaluate the long -term safety	24 months post-transplant
Secondary	Absence of RCL (Replication competent lentivirus)	To evaluate the long -term safety	24 months post-transplant
Secondary	Absence of clinically detectable malignancy or abnormal clonal dominance assessed as related to study treatment	To evaluate the long -term safety. It will be evaluated by vector insertion site analysis (VISA).	24 months post-transplant
Secondary	Protein expression through percentage of anti-sickling Hb	To evaluate the long -term efficacy	24 months post-transplant